一分钟看懂
这是一项关于前列腺癌的III 期研究，登记的药物或干预包括Ifinatamab deruxtecan；Docetaxel；Prednisone；Rescue Medication，当前状态为招募中。登记地点显示中国北京、重庆、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ifinatamab deruxtecan；Docetaxel；Prednisone；Rescue Medication · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University First Hospital ( Site 1434) · 北京
- Shanghai General Hospital ( Site 1449) · 北京
- The First Affiliated Hospital of Chonqing Medical University ( Site 1406) · 重庆
- Chongqing University Three Gorges Hospital ( Site 1405) · 重庆
- The First Affiliated Hospital Of Fujian Medical University ( Site 1452) · 福州
- Guangzhou First People's Hospital ( Site 1410) · 广州
- Sun Yat-Sen University Cancer Center ( Site 1467) · 广州
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 1402) · 广州
- Sun Yat-sen University Cancer Center ( Site 1409) · 广州
- The Fifth Affiliated Hospital of Sun Yat-Sen University ( Site 1459) · 珠海
- Guangxi Medical University Cancer Hospital ( Site 1414) · 南宁
- Henan Cancer Hospital ( Site 1472) · 郑州
- Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1424) · 武汉
- Hunan Cancer Hospital ( Site 1411) · 长沙
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 1425) · 南京
- Jiangsu Province Hospital ( Site 1426) · 南京
- Zhongda Hospital Southeast University ( Site 1427) · 南京
- The Affiliated Hospital of Xuzhou Medical University ( Site 1438) · 徐州
- Jilin Province People's Hospital ( Site 1461) · 长春
- The first affiliated Hospital of Xi an Jiaotong University ( Site 1408) · 西安
- Shandong Cancer Hospital ( Site 1421) · 济南
- Shanghai Tenth People's Hospital ( Site 1441) · 上海
- Fudan University Shanghai Cancer Center ( Site 1400) · 上海
- Zhongshan Hospital Fudan University ( Site 1430) · 上海
- Shanghai Tongji Hospital ( Site 1412) · 上海
- Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 1457) · 上海
- First Affiliated Hospital Of Shanxi Medical University ( Site 1460) · 太原
- West China Hospital of Sichuan University ( Site 1451) · 成都
- West China Hospital, Sichuan University ( Site 1468) · 成都
- The Affiliated Cancer Hospital of Xinjiang Medical University ( Site 1469) · 乌鲁木齐
- Zhejiang Cancer Hospital ( Site 1447) · 杭州
- The First Hospital of Jiaxing ( Site 1416) · 嘉兴
- The First Affiliated Hospital of Ningbo University ( Site 1419) · 宁波
- The First Affiliated Hospital of Wenzhou Medical University ( Site 1437) · 温州
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- * Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months prior to Screening
- * Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography (CT)/magnetic resonance imaging (MRI)
- * Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after at least 8 weeks of treatment
- * Has provided tumor tissue from a core or excisional biopsy from soft tissue not previously irradiated and obtained after disease progression on the most recent prior therapy
- * Has recovered from adverse events (AEs) due to previous anticancer therapies
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06925737；登记信息更新于 2026-09-17。